Vepdegestrant (ARV-471)

About Pfizer

Pfizer's mission is to deliver 'Breakthroughs that change patients' lives' through scientific innovation across a diversified portfolio of therapeutics and vaccines. Its strategic achievements include the rapid development and global commercialization of the COVID-19 vaccine Comirnaty, establishing a leading mRNA platform, and a disciplined pipeline expansion into high-growth areas like obesity and oncology. The company's strategy focuses on sharpening its R&D focus on transformative science, optimizing its cost structure, and deploying capital for strategic business development to drive long-term growth post-pandemic.

About Arvinas

Arvinas is a leader in the field of targeted protein degradation, developing novel therapeutics through its proprietary PROTAC® platform. The company has achieved significant clinical validation, with its lead oncology asset, vepdegestrant, demonstrating efficacy in pivotal trials for breast cancer, and its neuroscience candidate, ARV-102, showing compelling early-stage proof-of-concept in Parkinson's disease. Arvinas's strategy combines internal R&D with strategic partnerships, such as its major collaboration with Pfizer, to advance a deep pipeline and solidify its position as a platform innovator and drug developer.

Therapeutic Areas

Other ER+/HER2- Breast Cancer Drugs